The two collaborators have signed an agreement with the aim to advance genomics and precision medicine and its implementation in healthcare.
The joint partnership will focus on the development and implementation of innovative solutions and models to provide genomic-based precision medicine at a national level, state the collaborators.
“Denmark and Sweden have many similarities in our respective healthcare systems, but also differences to learn from.”
“Denmark and Sweden have many similarities in our respective healthcare systems, but also differences to learn from. The Danish National Genome Center, the Danish equivalent to Genomic Medicine Sweden will be an important partner in developing and exchanging experience and expertise on how to continue advance and implement precision medicine for the benefit of our patients and societies,” says Richard Rosenquist Brandell, Director for Genomic Medicine Sweden.
Tackle common challenges
In this strategic partnership, the Danish National Genome Center and Genomic Medicine Sweden will share experience of the implementation of genomics and precision medicine approaches in healthcare and mutually demonstrate the clinical utility of genomic medicine for different diseases. This partnership will promote faster and more successful advances by building common approaches for implementation of precision diagnostics and precision medicine in healthcare. This includes solutions and models for data processing and sharing, ethical issues and health economy.
“The MoU will facilitate further collaborative activities to help tackle some of our common challenges in implementing personalized medicine, such as within standardization as well as storage of and access to genomic data.”
”We look very much forward to share experiences with our Swedish neighbors. The MoU will facilitate further collaborative activities to help tackle some of our common challenges in implementing personalized medicine, such as within standardization as well as storage of and access to genomic data. Working together will ensure that patients receive the best treatment possible,” says Bettina Lundgren, CEO of the Danish National Genome Center.
The Memorandum of Understanding (MoU) was signed by Bettina Lundgren and Richard Rosenquist Brandell during the Nordic Precision Medicine Forum in Stockholm on April 28th where they took part to discuss the future developments of precision medicine.
Photo of Bettina Lundgren and Richard Rosenquist Brandell. Photographer: Lene Cividanes, Head of Research, Clinic and International Relations, Danish National Genome Centers.